Camille Sebaaly
About Camille Sebaaly
Camille Sebaaly is Chief Financial Officer of Sunshine Biopharma Inc. (SBFM), appointed October 15, 2009; he served as a director until resigning from the board in October 2021 . He is 64 and holds an Electrical & Computer Engineering degree from the State University of New York at Buffalo (1987) . Company performance under his finance leadership shows mixed signals: 2024 total shareholder return was -99.9% and net income was -$5,134,116, compared to 2023 TSR of 0% and net income of -$4,506,044 . Operationally, 2024 year-to-date revenue grew 54% and Q3 2024 revenue rose 42% year-over-year, reflecting growth in Nora Pharma’s generics portfolio .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Sunshine Biopharma Inc. | Chief Financial Officer | Oct 15, 2009 – present | Senior financial management; oversight of finance, business development, project management and investor relations . |
| Sunshine Biopharma Inc. | Director | Oct 15, 2009 – Oct 2021 | Board service prior to resignation in Oct 2021 . |
| Nora Pharma Inc. (wholly-owned subsidiary) | Secretary | Jan 1, 2024 – present | Corporate secretary responsibilities concurrent with CFO role, dedicating substantial time to Nora operations . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Independent (Consulting) | Business Consultant (biotech/biopharma) | 2001 – present | Senior executive roles in financial management, business development, project management; strategic planning and deal execution . |
Fixed Compensation
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Base Salary ($) | $300,000 | $315,000 | $302,031 |
| Target Bonus % | Not disclosed | Not disclosed | Not disclosed |
| Actual Bonus Paid ($) | $630,000 | $380,000 | $50,000 |
| Option/Stock Awards ($) | $0 | $0 | $0 |
| Total ($) | $930,000 | $695,000 | $352,031 |
Performance Compensation
- The company states it “currently do[es] not use” financial metrics (Net Income, Net Sales, Operating Income) in executive compensation; equity compensation is not used, so stock value does not impact pay .
| Component | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Annual Cash Bonus 2022 | None specified | n/a | n/a | Discretionary | $630,000 | n/a |
| Annual Cash Bonus 2023 | None specified | n/a | n/a | Discretionary | $380,000 | n/a |
| Annual Cash Bonus 2024 | None specified | n/a | n/a | Discretionary | $50,000 | n/a |
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Total Beneficial Ownership | 60 common shares; less than 1% of common shares outstanding . |
| Preferred Stock | No Series B Preferred held (all 130,000 Series B shares held by CEO) . |
| Vested vs. Unvested | No outstanding equity awards company-wide as of Dec 31, 2024 . |
| Options (Exercisable/Unexercisable) | None outstanding . |
| Shares Pledged | No pledging disclosure for Sebaaly in proxy; not indicated . |
| Ownership Guidelines | Not disclosed . |
| Equity Plan Status | 2023 Equity Incentive Plan increased to 683,000 shares; no grants made as of Dec 31, 2024 . |
| Fair Market Value Reference | $1.84 per share on Oct 22, 2025 (plan disclosure) . |
| Insider Trading Activity | Form 4 buy of 30,000 shares at $0.76 in Nov 2022 (aggregator references) . |
Employment Terms
| Term | CFO Agreement (Oct 21, 2024; effective Jan 1, 2024) |
|---|---|
| Base Salary | CAD $411,000; paid biweekly; annual increase minimum 5% or US CPI . |
| Bonus Eligibility | Annualized bonus at Board’s discretion . |
| Benefits | Eligible for stock options (plan), health, life insurance, retirement plans . |
| Term | Indefinite . |
| Role Scope | CFO (SBFM) and Secretary (Nora Pharma); ~90% time dedicated to Nora . |
| Severance (Without Cause) | CAD $2,000,000 plus statutory notice; settlement of all claims . |
| Vacation | 3 weeks per year; May 1–April 30 reference period . |
| Non-Compete / Non-Solicit | Referenced in Schedule B (ND/NC/NS agreement) appended; specific durations not disclosed in excerpt . |
| Applicable Law / Jurisdiction | Province of Quebec; district of Montreal (non-exclusive jurisdiction) . |
| Insider Trading Policy | Company insider trading policy adopted; filed as an exhibit to 2024 10-K . |
| Change-in-Control (Plan) | Committee may accelerate/cancel/replace awards under 2023 Plan; not automatic; CFO has no outstanding awards currently |
Board Governance (context)
- Sebaaly is not currently a director (resigned Oct 2021) . Compensation Committee comprises independent directors; it did not meet separately in 2024 . Audit Committee and Nominating/Governance Committee compositions and inactivity noted for 2024 .
Performance & Track Record
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income ($) | (4,506,044) | (5,134,116) |
| Total Shareholder Return | 0% (base $1 on 12/31/2022) | (99.9%) |
| Revenue Growth (Operational) | — | YTD +54%; Q3 +42% YoY |
Investment Implications
- Compensation alignment: Predominantly cash-based with discretionary bonuses and no formal performance metric linkage; no equity awards outstanding, weakening long-term alignment and reducing vesting-related selling pressure .
- Retention economics: Indefinite-term employment with a sizable CAD $2,000,000 severance for termination without cause; modest 3-week vacation and annual salary escalator (≥5% or CPI) provide stability but increase fixed costs .
- Ownership signal: Current beneficial ownership is minimal (60 shares, <1%); historical Form 4 indicates at least one purchase (Nov 2022), but present equity stake and lack of pledging disclosure suggest limited “skin in the game” .
- Performance risk: Despite strong reported revenue growth in 2024, TSR collapsed and net losses widened; with bonuses discretionary and not tied to defined financial KPIs, investors should monitor any adoption of metric-based incentives and potential future equity grants under the expanded 2023 Plan .